GlassScriptPhysician profile
Gary S Yashinsky
NPI 1649271115
$10,866.45
in general payments reported to CMS, 2019-2025
45 companies · $2,549 in 2025
The $2,549 reported for 2025 was more than what 95% of Internal Medicine providers received nationally (typical 2025 total: $156).
Payments by year
General payments by program year, as reported to CMS.
General payments by year: 2019: $1,789 · 2020: $434 · 2021: $317 · 2022: $1,270 · 2023: $2,074 · 2024: $2,434 · 2025: $2,549.
What the payments were for
Nature of payment as categorized by the reporting companies: meals, consulting, travel, and so on.
Food and Beverage: $7,057.
View as a table
| Payment type | Amount (2023-2025) |
|---|---|
| Food and Beverage | $7,056.56 |
Payment-type detail covers 2023-2025; earlier years are included in totals but not broken out here.
Who reported paying
General payments only, as reported to CMS. Product names cover 2023-2025.
| Company | General payments | Years | Top products |
|---|---|---|---|
| Novo Nordisk INC | $2,611.56 | 2019-2025 | Ozempic, Rybelsus, Wegovy |
| Astrazeneca Pharmaceuticals LP | $1,700.76 | 2019-2025 | Airsupra, Farxiga, Breztri |
| Bayer Healthcare Pharmaceuticals INC. | $722.31 | 2022-2024 | |
| Xeris Pharmaceuticals, INC. | $615.11 | 2022-2025 | Gvoke Hypopen |
| Boehringer Ingelheim Pharmaceuticals, INC. | $508.24 | 2021-2025 | Jardiance, Ofev, Jascayd |
| Lilly USA, LLC | $409.06 | 2019-2025 | Mounjaro, Jardiance, Zepbound |
| Janssen Pharmaceuticals, INC | $373.68 | 2019-2022 | |
| Abbvie INC. | $360.12 | 2019-2025 | Vraylar |
| Amgen INC. | $354.03 | 2019-2025 | Repatha, Repatha, Otezla |
| Pfizer INC. | $344.39 | 2019-2025 | |
| Novartis Pharmaceuticals Corporation | $330.95 | 2019-2023 | |
| Abbott Laboratories | $319.84 | 2022-2025 | Freestyle Libre 3, Freestyle Libre 2 |
| Sumitomo Pharma America, INC. | $280.18 | 2024-2025 | Gemtesa, Myfembree |
| Glaxosmithkline, LLC. | $265.75 | 2019-2025 | Trelegy Ellipta, Arexvy, Shingrix |
| Astellas Pharma US INC | $201.85 | 2019-2023 | Veozah, Myrbetriq |
Show all 45 companies
| Company | General payments | Years | Top products |
|---|---|---|---|
| Medtronic, INC. | $118.10 | 2025 | Symplicity G3 |
| Exact Sciences Corporation | $111.38 | 2023-2024 | Cologuard Collection Kit |
| Ablative Solutions, INC. | $109.09 | 2020 | |
| Amneal Pharmaceuticals LLC | $103.96 | 2023-2024 | Unithroid |
| Dexcom, INC. | $87.23 | 2023-2025 | Dexcom G6 Transmitter |
| Otsuka America Pharmaceutical, INC. | $81.44 | 2024-2025 | Rexulti |
| Esperion Therapeutics, INC. | $80.90 | 2023-2025 | Nexletol |
| Takeda Pharmaceuticals U.S.A., INC. | $75.29 | 2019-2025 | Vpriv |
| Genzyme Corporation | $70.00 | 2019 | |
| Merck Sharp & Dohme LLC | $66.12 | 2019-2023 | Verquvo, Steglatro, Belsomra |
| Lundbeck LLC | $54.29 | 2025 | Rexulti |
| Corium, LLC | $53.71 | 2022-2023 | Adlarity |
| Dynavax Technologies Corporation | $49.12 | 2024-2025 | Heplisav-B |
| Biohaven Pharmaceutical Holding Company LTD. | $36.93 | 2022 | |
| Sanofi-Aventis U.S. LLC | $35.92 | 2019-2023 | |
| Actelion Pharmaceuticals US, INC. | $35.33 | 2024-2025 | Opsumit, Uptravi |
| Amarin Pharma, INC. | $31.68 | 2019 | |
| Axsome Therapeutics, INC. | $30.26 | 2024 | Auvelity |
| Alexion Pharmaceuticals, INC. | $28.94 | 2019 | |
| Ucb, INC. | $26.62 | 2024 | Nayzilam |
| Salix Pharmaceuticals, A Division of Bausch Health US, LLC | $26.28 | 2019-2023 | Xifaxan |
| Phathom Pharmaceuticals, INC. | $24.73 | 2024 | Voquezna |
| Vanda Pharmaceuticals INC. | $23.44 | 2020 | |
| Shield Therapeutics INC | $20.02 | 2023 | Accrufer |
| Pulmonx Corporation | $16.06 | 2024 | Zephyr Delivery Catheter, Pulmonx Chartis Tablet Console, Chartis Catheter |
| Promius Pharma LLC | $15.47 | 2019 | |
| Gilead Sciences, INC. | $14.58 | 2025 | |
| Hikma Pharmaceuticals USA | $14.30 | 2023 | Mitigare |
| Ibsa Pharma INC. | $14.10 | 2023 | Tirosint, Licart |
| Currax Pharmaceuticals LLC | $13.33 | 2023 | Contrave |
Drugs and devices associated with these payments
CMS records which products a payment was associated with, not how the money was allocated. Association is not allocation: one payment can be associated with several products, and a product listing does not mean the payment was made because of that product. Product detail covers 2023-2025.
If you want to bring it up
Most clinicians are glad to talk about this. A respectful way in:
- "I saw Gary Yashinsky listed in the CMS Open Payments database. Can you tell me about your work with those companies?"
- "Is there a generic or alternative to this medication, and would it work as well for me?"
- "What made you choose this particular treatment for my situation?"
These are normal questions. A good clinician will welcome them.
Share this page
Keep an eye on this page
Get an email when the next June refresh changes this page. No account needed.
Source: CMS Open Payments, program years 2019-2025, as reported to CMS by drug and device makers (published June 30, 2026). Drug and device detail covers 2023-2025.